Compare IDXX & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | HLN |
|---|---|---|
| Founded | 1983 | 2022 |
| Country | United States | United Kingdom |
| Employees | N/A | 24524 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6B | 41.1B |
| IPO Year | 1996 | N/A |
| Metric | IDXX | HLN |
|---|---|---|
| Price | $562.15 | $9.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $721.67 | N/A |
| AVG Volume (30 Days) | 564.7K | ★ 9.0M |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 3.47 | N/A |
| Revenue | ★ $4,303,702,000.00 | N/A |
| Revenue This Year | $10.88 | $6.55 |
| Revenue Next Year | $8.59 | $4.42 |
| P/E Ratio | $162.76 | ★ $49.05 |
| Revenue Growth | ★ 10.42 | N/A |
| 52 Week Low | $507.55 | $8.65 |
| 52 Week High | $769.98 | $11.28 |
| Indicator | IDXX | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 48.07 |
| Support Level | $550.28 | $9.04 |
| Resistance Level | $589.82 | $9.44 |
| Average True Range (ATR) | 15.41 | 0.12 |
| MACD | 2.25 | 0.00 |
| Stochastic Oscillator | 64.65 | 63.27 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.